ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsPrognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events in advanced hepatitis C virus (HCV)-related liver disease.
methodsnordicPRO-C6 was assessed in baseline serum from 339 patients with advanced liver fibrosis from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. The prognostic value of PRO-C6 was evaluated.
resultsBaseline serum levels of PRO-C6 were significantly higher in patients with cirrhosis and PRO-C6 was an independent prognostic marker for liver-related events. Each doubling of PRO-C6 was associated with increased hazard of liver-related events in all patients (hazard ratio (HR) = 2.22, 95% confidence interval (CI) 1.57-3.14, p < 0.0001), and in patients with cirrhosis (HR = 1.71, 95% CI 1.14-2.58, p = 0.01).
conclusionEndotrophin assessed by PRO-C6 is an independent prognostic marker for liver-related events in patients with advanced liver fibrosis and ongoing inflammation due to HCV, particularly in those with cirrhosis, from the HALT-C trial. PRO-C6 may be useful for risk stratification in end-stage liver disease. However, validation in non-interferon-treated cohorts and across chronic liver diseases of varying etiologies is required to confirm its prognostic value for liver-related events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.